View ValuationBiofarm 将来の成長Future 基準チェック /06現在、 Biofarmの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.46, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 150% over the past three years.お知らせ • May 08Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion.Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion on May 6, 2026. A cash consideration valued at RON 1.379 per share will be paid by Polpharma SA Pharmaceutical Works, nearly 15% above the market price at the time the announcement was made. The price of Biofarm’s shares increased by 2.9% on May 7, 2026. Each of Longshield Investment Group SA and Lion Capital S.A. have undertaken to tender in such VTO all of their shares held in Biofarm. Separately, Lion Capital S.A. as shareholder of Biofarm S.A. entered into an implementation agreement with Longshield Investment Group S.A. and Zaklady Farmaceutyczne Polpharma S.A. The launch of the VTO is subject to obtaining all relevant approvals from the Financial Supervisory Authority. A special dividend of RON 0.140263 per share is intended to be distributed to all of the legally entitled shareholders of Biofarm, subject to approval by the general meeting of its shareholders before the launch of the VTO.Upcoming Dividend • May 06Upcoming dividend of RON0.042 per shareEligible shareholders must have bought the stock before 13 May 2026. Payment date: 29 May 2026. Payout ratio is a comfortable 41% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Romanian dividend payers (6.6%). Higher than average of industry peers (2.8%).分析記事 • Apr 01Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...お知らせ • Mar 26Biofarm S.A. announces Annual dividend, payable on May 29, 2026Biofarm S.A. announced Annual dividend of RON 0.0420 per share payable on May 29, 2026, ex-date on May 13, 2026 and record date on May 14, 2026.お知らせ • Mar 24Biofarm S.A., Annual General Meeting, Apr 28, 2026Biofarm S.A., Annual General Meeting, Apr 28, 2026, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99 logofatul tautu street, 3rd district., RomaniaReported Earnings • Mar 04Full year 2025 earnings released: EPS: RON0.10 (vs RON0.076 in FY 2024)Full year 2025 results: EPS: RON0.10 (up from RON0.076 in FY 2024). Revenue: RON330.4m (up 15% from FY 2024). Net income: RON100.8m (up 36% from FY 2024). Profit margin: 31% (up from 26% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.34, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 125% over the past three years.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 26%After last week's 26% share price gain to RON1.05, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 82% over the past three years.お知らせ • Jan 14+ 3 more updatesBiofarm S.A. to Report Q4, 2025 Results on Feb 27, 2026Biofarm S.A. announced that they will report Q4, 2025 results on Feb 27, 2026Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON100.8m (up 12% from 3Q 2024). Net income: RON38.3m (up 22% from 3Q 2024). Profit margin: 38% (up from 35% in 3Q 2024). The increase in margin was driven by higher revenue.Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: RON0.017 (vs RON0.022 in 2Q 2024)Second quarter 2025 results: EPS: RON0.017 (down from RON0.022 in 2Q 2024). Revenue: RON68.3m (down 2.0% from 2Q 2024). Net income: RON16.5m (down 23% from 2Q 2024). Profit margin: 24% (down from 31% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Aug 11Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 18 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Romanian dividend payers (6.3%). Higher than average of industry peers (3.1%).Reported Earnings • May 16First quarter 2025 earnings released: EPS: RON0.033 (vs RON0.021 in 1Q 2024)First quarter 2025 results: EPS: RON0.033 (up from RON0.021 in 1Q 2024). Revenue: RON95.1m (up 33% from 1Q 2024). Net income: RON32.3m (up 57% from 1Q 2024). Profit margin: 34% (up from 29% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.Declared Dividend • Mar 24Dividend of RON0.031 announcedDividend of RON0.031 is the same as last year. Ex-date: 18th August 2025 Payment date: 5th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but not covered by cash flows (125% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 7.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Mar 23Biofarm S.A. announces Annual dividend, payable on September 05, 2025Biofarm S.A. announced Annual dividend of RON 0.0310 per share payable on September 05, 2025, ex-date on August 18, 2025 and record date on August 19, 2025.お知らせ • Mar 21Biofarm S.A., Annual General Meeting, Apr 28, 2025Biofarm S.A., Annual General Meeting, Apr 28, 2025, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99, logofatul tautu street, 3rd district., bucharest RomaniaNew Risk • Mar 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RON67.2m (US$14.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 06Full year 2024 earnings released: EPS: RON0.076 (vs RON0.078 in FY 2023)Full year 2024 results: EPS: RON0.076 (down from RON0.078 in FY 2023). Revenue: RON287.2m (up 2.5% from FY 2023). Net income: RON74.4m (down 3.4% from FY 2023). Profit margin: 26% (down from 28% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON70.0m (up 5.5% from 2Q 2023). Net income: RON21.4m (up 16% from 2Q 2023). Profit margin: 31% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue.Upcoming Dividend • Aug 13Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 20 August 2024. Payment date: 06 September 2024. Payout ratio is a comfortable 46% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.2%).Reported Earnings • Apr 30Full year 2023 earnings released: EPS: RON0.078 (vs RON0.072 in FY 2022)Full year 2023 results: EPS: RON0.078 (up from RON0.072 in FY 2022). Revenue: RON280.3m (up 1.2% from FY 2022). Net income: RON77.0m (up 8.6% from FY 2022). Profit margin: 28% (up from 26% in FY 2022). The increase in margin was primarily driven by lower expenses. Post-clinical trial products Launched (during full year): 11 Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 8% per year.Reported Earnings • Nov 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: RON67.3m (down 4.3% from 3Q 2022). Net income: RON19.8m (down 10% from 3Q 2022). Profit margin: 30% (down from 31% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Non-Executive Non-Independent Director Marian Buica Nicusor was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: RON66.5m (up 6.0% from 2Q 2022). Net income: RON18.5m (up 8.5% from 2Q 2022). Profit margin: 28% (in line with 2Q 2022).Upcoming Dividend • Aug 14Upcoming dividend of RON0.03 per share at 4.3% yieldEligible shareholders must have bought the stock before 21 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 39% and the cash payout ratio is 85%. Trailing yield: 4.3%. Lower than top quartile of Romanian dividend payers (8.4%). Higher than average of industry peers (2.5%).Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: RON71.0m (up 17% from 3Q 2021). Net income: RON22.1m (up 20% from 3Q 2021). Profit margin: 31% (in line with 3Q 2021).Buying Opportunity • Aug 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.Upcoming Dividend • Aug 15Upcoming dividend of RON0.024 per shareEligible shareholders must have bought the stock before 22 August 2022. Payment date: 09 September 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.8%).Buying Opportunity • May 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.Reported Earnings • Mar 03Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.061 (up from RON0.055 in FY 2020). Revenue: RON240.3m (up 11% from FY 2020). Net income: RON60.0m (up 11% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Aug 09Upcoming dividend of RON0.022 per shareEligible shareholders must have bought the stock before 16 August 2021. Payment date: 03 September 2021. Trailing yield: 3.7%. Lower than top quartile of Romanian dividend payers (5.6%). Higher than average of industry peers (2.7%).Reported Earnings • May 19First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: RON62.8m (down 2.0% from 1Q 2020). Net income: RON22.5m (up 21% from 1Q 2020). Profit margin: 36% (up from 29% in 1Q 2020). The increase in margin was driven by lower expenses.分析記事 • Mar 18Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Biofarm's (BVB:BIO) stock is up by a considerable 40% over the past three months. Given that the market rewards strong...分析記事 • Feb 18Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...Is New 90 Day High Low • Feb 17New 90-day high: RON0.53The company is up 28% from its price of RON0.41 on 19 November 2020. The Romanian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.分析記事 • Jan 23Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total ReturnWhen we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...Is New 90 Day High Low • Jan 11New 90-day high: RON0.45The company is up 10.0% from its price of RON0.41 on 13 October 2020. The Romanian market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.分析記事 • Dec 25A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)Today we will run through one way of estimating the intrinsic value of Biofarm S.A. ( BVB:BIO ) by taking the expected...Is New 90 Day High Low • Dec 22New 90-day high: RON0.42The company is up 3.0% from its price of RON0.40 on 23 September 2020. The Romanian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.分析記事 • Dec 03Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?The big shareholder groups in Biofarm S.A. ( BVB:BIO ) have power over the company. Institutions often own shares in...Is New 90 Day High Low • Oct 16New 90-day low: RON0.39The company is down 5.0% from its price of RON0.41 on 17 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.Is New 90 Day High Low • Sep 30New 90-day low: RON0.40The company is down 2.0% from its price of RON0.41 on 02 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Biofarm は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BVB:BIO - アナリストの将来予測と過去の財務データ ( )RON Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20263171017593N/A12/31/20253191016681N/A9/30/20253198890104N/A6/30/2025309817691N/A3/31/2025310866379N/A12/31/2024287743458N/A9/30/2024282802462N/A6/30/2024259693573N/A3/31/202425666744N/A12/31/2023280775080N/A9/30/2023297752549N/A6/30/2023301772953N/A3/31/2023297762650N/A12/31/202227771-129N/A9/30/2022269711241N/A6/30/202226068-169N/A3/31/2022253654168N/A12/31/2021239604869N/A9/30/2021241645479N/A6/30/2021231616593N/A3/31/2021215581544N/A12/31/2020216541240N/A9/30/2020214561144N/A6/30/2020205523252N/A3/31/202021153N/AN/AN/A12/31/201919551N/A73N/A9/30/201918942N/AN/AN/A6/30/201919544N/A68N/A3/31/201918943N/AN/AN/A12/31/201818438N/A46N/A9/30/201817943N/AN/AN/A6/30/201817138N/A49N/A3/31/201817639N/AN/AN/A12/31/201717036N/A37N/A9/30/201716735N/AN/AN/A6/30/201716535N/A32N/A3/31/201715532N/AN/AN/A12/31/201615229N/A40N/A9/30/201614929N/AN/AN/A6/30/201614827N/A24N/A3/31/201613820N/AN/AN/A12/31/201514927N/A24N/A9/30/201514727N/AN/AN/A6/30/201513827N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIOの予測収益成長が 貯蓄率 ( 6.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIOの収益がRO市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIOの収益がRO市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BIOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 00:03終値2026/05/27 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biofarm S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Vladimira UrbankovaErste Group Bank AGRaluca FloreaErste Group Bank AG
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.46, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 150% over the past three years.
お知らせ • May 08Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion.Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion on May 6, 2026. A cash consideration valued at RON 1.379 per share will be paid by Polpharma SA Pharmaceutical Works, nearly 15% above the market price at the time the announcement was made. The price of Biofarm’s shares increased by 2.9% on May 7, 2026. Each of Longshield Investment Group SA and Lion Capital S.A. have undertaken to tender in such VTO all of their shares held in Biofarm. Separately, Lion Capital S.A. as shareholder of Biofarm S.A. entered into an implementation agreement with Longshield Investment Group S.A. and Zaklady Farmaceutyczne Polpharma S.A. The launch of the VTO is subject to obtaining all relevant approvals from the Financial Supervisory Authority. A special dividend of RON 0.140263 per share is intended to be distributed to all of the legally entitled shareholders of Biofarm, subject to approval by the general meeting of its shareholders before the launch of the VTO.
Upcoming Dividend • May 06Upcoming dividend of RON0.042 per shareEligible shareholders must have bought the stock before 13 May 2026. Payment date: 29 May 2026. Payout ratio is a comfortable 41% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Romanian dividend payers (6.6%). Higher than average of industry peers (2.8%).
分析記事 • Apr 01Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...
お知らせ • Mar 26Biofarm S.A. announces Annual dividend, payable on May 29, 2026Biofarm S.A. announced Annual dividend of RON 0.0420 per share payable on May 29, 2026, ex-date on May 13, 2026 and record date on May 14, 2026.
お知らせ • Mar 24Biofarm S.A., Annual General Meeting, Apr 28, 2026Biofarm S.A., Annual General Meeting, Apr 28, 2026, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99 logofatul tautu street, 3rd district., Romania
Reported Earnings • Mar 04Full year 2025 earnings released: EPS: RON0.10 (vs RON0.076 in FY 2024)Full year 2025 results: EPS: RON0.10 (up from RON0.076 in FY 2024). Revenue: RON330.4m (up 15% from FY 2024). Net income: RON100.8m (up 36% from FY 2024). Profit margin: 31% (up from 26% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.34, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 125% over the past three years.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 26%After last week's 26% share price gain to RON1.05, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 82% over the past three years.
お知らせ • Jan 14+ 3 more updatesBiofarm S.A. to Report Q4, 2025 Results on Feb 27, 2026Biofarm S.A. announced that they will report Q4, 2025 results on Feb 27, 2026
Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON100.8m (up 12% from 3Q 2024). Net income: RON38.3m (up 22% from 3Q 2024). Profit margin: 38% (up from 35% in 3Q 2024). The increase in margin was driven by higher revenue.
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: RON0.017 (vs RON0.022 in 2Q 2024)Second quarter 2025 results: EPS: RON0.017 (down from RON0.022 in 2Q 2024). Revenue: RON68.3m (down 2.0% from 2Q 2024). Net income: RON16.5m (down 23% from 2Q 2024). Profit margin: 24% (down from 31% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Aug 11Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 18 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Romanian dividend payers (6.3%). Higher than average of industry peers (3.1%).
Reported Earnings • May 16First quarter 2025 earnings released: EPS: RON0.033 (vs RON0.021 in 1Q 2024)First quarter 2025 results: EPS: RON0.033 (up from RON0.021 in 1Q 2024). Revenue: RON95.1m (up 33% from 1Q 2024). Net income: RON32.3m (up 57% from 1Q 2024). Profit margin: 34% (up from 29% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.
Declared Dividend • Mar 24Dividend of RON0.031 announcedDividend of RON0.031 is the same as last year. Ex-date: 18th August 2025 Payment date: 5th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but not covered by cash flows (125% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 7.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 23Biofarm S.A. announces Annual dividend, payable on September 05, 2025Biofarm S.A. announced Annual dividend of RON 0.0310 per share payable on September 05, 2025, ex-date on August 18, 2025 and record date on August 19, 2025.
お知らせ • Mar 21Biofarm S.A., Annual General Meeting, Apr 28, 2025Biofarm S.A., Annual General Meeting, Apr 28, 2025, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99, logofatul tautu street, 3rd district., bucharest Romania
New Risk • Mar 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RON67.2m (US$14.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 06Full year 2024 earnings released: EPS: RON0.076 (vs RON0.078 in FY 2023)Full year 2024 results: EPS: RON0.076 (down from RON0.078 in FY 2023). Revenue: RON287.2m (up 2.5% from FY 2023). Net income: RON74.4m (down 3.4% from FY 2023). Profit margin: 26% (down from 28% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.
Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON70.0m (up 5.5% from 2Q 2023). Net income: RON21.4m (up 16% from 2Q 2023). Profit margin: 31% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue.
Upcoming Dividend • Aug 13Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 20 August 2024. Payment date: 06 September 2024. Payout ratio is a comfortable 46% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.2%).
Reported Earnings • Apr 30Full year 2023 earnings released: EPS: RON0.078 (vs RON0.072 in FY 2022)Full year 2023 results: EPS: RON0.078 (up from RON0.072 in FY 2022). Revenue: RON280.3m (up 1.2% from FY 2022). Net income: RON77.0m (up 8.6% from FY 2022). Profit margin: 28% (up from 26% in FY 2022). The increase in margin was primarily driven by lower expenses. Post-clinical trial products Launched (during full year): 11 Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 8% per year.
Reported Earnings • Nov 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: RON67.3m (down 4.3% from 3Q 2022). Net income: RON19.8m (down 10% from 3Q 2022). Profit margin: 30% (down from 31% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Non-Executive Non-Independent Director Marian Buica Nicusor was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: RON66.5m (up 6.0% from 2Q 2022). Net income: RON18.5m (up 8.5% from 2Q 2022). Profit margin: 28% (in line with 2Q 2022).
Upcoming Dividend • Aug 14Upcoming dividend of RON0.03 per share at 4.3% yieldEligible shareholders must have bought the stock before 21 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 39% and the cash payout ratio is 85%. Trailing yield: 4.3%. Lower than top quartile of Romanian dividend payers (8.4%). Higher than average of industry peers (2.5%).
Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: RON71.0m (up 17% from 3Q 2021). Net income: RON22.1m (up 20% from 3Q 2021). Profit margin: 31% (in line with 3Q 2021).
Buying Opportunity • Aug 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.
Upcoming Dividend • Aug 15Upcoming dividend of RON0.024 per shareEligible shareholders must have bought the stock before 22 August 2022. Payment date: 09 September 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.8%).
Buying Opportunity • May 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.
Reported Earnings • Mar 03Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.061 (up from RON0.055 in FY 2020). Revenue: RON240.3m (up 11% from FY 2020). Net income: RON60.0m (up 11% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Aug 09Upcoming dividend of RON0.022 per shareEligible shareholders must have bought the stock before 16 August 2021. Payment date: 03 September 2021. Trailing yield: 3.7%. Lower than top quartile of Romanian dividend payers (5.6%). Higher than average of industry peers (2.7%).
Reported Earnings • May 19First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: RON62.8m (down 2.0% from 1Q 2020). Net income: RON22.5m (up 21% from 1Q 2020). Profit margin: 36% (up from 29% in 1Q 2020). The increase in margin was driven by lower expenses.
分析記事 • Mar 18Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Biofarm's (BVB:BIO) stock is up by a considerable 40% over the past three months. Given that the market rewards strong...
分析記事 • Feb 18Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Is New 90 Day High Low • Feb 17New 90-day high: RON0.53The company is up 28% from its price of RON0.41 on 19 November 2020. The Romanian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
分析記事 • Jan 23Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total ReturnWhen we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...
Is New 90 Day High Low • Jan 11New 90-day high: RON0.45The company is up 10.0% from its price of RON0.41 on 13 October 2020. The Romanian market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
分析記事 • Dec 25A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)Today we will run through one way of estimating the intrinsic value of Biofarm S.A. ( BVB:BIO ) by taking the expected...
Is New 90 Day High Low • Dec 22New 90-day high: RON0.42The company is up 3.0% from its price of RON0.40 on 23 September 2020. The Romanian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
分析記事 • Dec 03Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?The big shareholder groups in Biofarm S.A. ( BVB:BIO ) have power over the company. Institutions often own shares in...
Is New 90 Day High Low • Oct 16New 90-day low: RON0.39The company is down 5.0% from its price of RON0.41 on 17 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Sep 30New 90-day low: RON0.40The company is down 2.0% from its price of RON0.41 on 02 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.